公开(公告)号：US10201607B2

公开(公告)日：2019-02-12

申请号：US15938961

申请日：2018-03-28

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US09598493B2

公开(公告)日：2017-03-21

申请号：US14592558

申请日：2015-01-08

Applicant: GENMAB A/S

Inventor： Janine Schuurman ,  Catharina Emanuele Gerarda Havenith ,  Paul Parren ,  Jan G. J. Van De Winkel ,  Denise Leah Williams ,  Jørgen Petersen ,  Ole Baadsgaard

IPC: C07K16/28 ,  G01N33/68 ,  A61K39/395 ,  A61K45/06 ,  A61N5/06 ,  C07K16/42 ,  C07K16/46 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/062 ,  C07K16/4258 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/6854 ,  G01N33/6869 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2333/7155

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US20150368345A1

公开(公告)日：2015-12-24

申请号：US14739771

申请日：2015-06-15

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Laster

IPC: C07K16/28

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of lgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Abstract translation: 本发明涉及抗体的恒定区，特别是1gG4的CH3区，其影响CH3-CH3相互作用强度的位置。 公开了稳定或不稳定这种相互作用的突变。

公开(公告)号：US20130345406A1

公开(公告)日：2013-12-26

申请号：US13912581

申请日：2013-06-07

Applicant: Genmab A/S

Inventor： Jan Van De Winkel ,  Tom Vink ,  Janine Schuurman ,  Paul Parren ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschoten

IPC: C07K16/18 ,  C07K16/16

CPC classification number: C07K16/2887 ,  A61K47/6803 ,  A61K47/6813 ,  A61K47/6835 ,  A61K47/6839 ,  A61K47/6845 ,  A61K47/6849 ,  A61K51/10 ,  A61K51/1006 ,  A61K51/1021 ,  A61K51/1027 ,  A61K51/103 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/16 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/94

Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Abstract translation: 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。

公开(公告)号：US20230227495A1

公开(公告)日：2023-07-20

申请号：US17939736

申请日：2022-09-07

Applicant: Genmab A/S

Inventor： Michael GRAMER ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kampen ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Amout F. Gerritsen

IPC: C07K1/113 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K1/1133 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/90

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

公开(公告)号：US11492371B2

公开(公告)日：2022-11-08

申请号：US16426647

申请日：2019-05-30

Applicant: GENMAB A/S

Inventor： Michael Gramer ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kampen ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Arnout F. Gerritsen

IPC: C07K1/113 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

公开(公告)号：US11359015B2

公开(公告)日：2022-06-14

申请号：US15744317

申请日：2016-07-14

Applicant: GENMAB A/S

Inventor： Rik Rademaker ,  Isil Altintas ,  Patrick Engelberts ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US11008399B2

公开(公告)日：2021-05-18

申请号：US17077376

申请日：2020-10-22

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US10793640B2

公开(公告)日：2020-10-06

申请号：US15627921

申请日：2017-06-20

Applicant: GENMAB A/S

Inventor： Bart De Goeij ,  Edward N. Van Den Brink ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  David Satijn ,  Jan Van De Winkel ,  Paul Parren

IPC: C07K16/30 ,  A61K39/395 ,  C07K16/32 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US10765743B2

公开(公告)日：2020-09-08

申请号：US16248402

申请日：2019-01-15

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  A61K39/00 ,  C07K16/30

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.